ReviewLipids in health and disease2013
Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies.
Review in Lipids in health and disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Review
- Effect of metformin on cell proliferation and apoptosis in steatosis HepG2 cell model.Northern clinics of Istanbul · 2025Article
- The Potential of Lamiaceae Herbs for Mitigation of Overweight, Obesity, and Fatty Liver: Studies and Perspectives.Molecules (Basel, Switzerland) · 2022Review
- The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).Molecular medicine (Cambridge, Mass.) · 2020Article
- Uncarboxylated osteocalcin ameliorates hepatic glucose and lipid metabolism in KKAy mice via activating insulin signaling pathway.Acta pharmacologica Sinica · 2020Article
- Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC.Frontiers in oncology · 2020Article
- Effect of dietary oils from various sources on carbohydrate and fat metabolism in mice.Food & nutrition research · 2020Article
- Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4.The Journal of international medical research · 2019Article
- Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver.Scientific reports · 2019Article
- Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.Current medical science · 2019Article
- Article
- Article
- Polyphenolic extract attenuates fatty acid-induced steatosis and oxidative stress in hepatic and endothelial cells.European journal of nutrition · 2018Article
- Impairment of Akt activity by CYP2E1 mediated oxidative stress is involved in chronic ethanol-induced fatty liver.Redox biology · 2018Article
- In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model.Lipids in health and disease · 2018Article
- The Nutraceutic Silybin Counteracts Excess Lipid Accumulation and Ongoing Oxidative Stress in anFrontiers in nutrition · 2017Article
- Article
- Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells.World journal of gastroenterology · 2016Article
- Endocrine causes of nonalcoholic fatty liver disease.World journal of gastroenterology · 2015Review
- The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Along with rising numbers of patients with metabolic syndrome, the prevalence of nonalcoholic fatty liver disease (NAFLD) has increased in proportion with the obesity epidemic. While there are no established treatments for NAFLD, current research is targeting new molecular mechanisms that underlie NAFLD and associated metabolic disorders. This review discusses some of these emerging molecular mechanisms and their therapeutic implications for the treatment of NAFLD. The basic research that has identified potential molecular targets for pharmacotherapy will be outlined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.